Twist Bioscience (NASDAQ:TWST) Trading 8% Higher – Should You Buy?

Twist Bioscience Co. (NASDAQ:TWST)’s stock price traded up 8% on Friday . The company traded as high as $47.37 and last traded at $47.13. 370,973 shares were traded during trading, a decline of 60% from the average session volume of 938,184 shares. The stock had previously closed at $43.62.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TWST. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Scotiabank upped their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Barclays reduced their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Robert W. Baird upped their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Finally, Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $51.90.

Twist Bioscience Stock Up 9.5 %

The firm has a market cap of $2.84 billion, a PE ratio of -13.27 and a beta of 1.82. The firm’s fifty day simple moving average is $45.24 and its two-hundred day simple moving average is $46.79.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 14,334 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $639,296.40. Following the sale, the chief executive officer now owns 589,552 shares in the company, valued at $26,294,019.20. The trade was a 2.37 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paula Green sold 860 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the transaction, the senior vice president now owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. The trade was a 0.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 99,659 shares of company stock worth $4,484,602. 3.92% of the stock is owned by corporate insiders.

Institutional Trading of Twist Bioscience

Several hedge funds have recently modified their holdings of the company. State Street Corp raised its stake in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Twist Bioscience by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after buying an additional 26,145 shares during the last quarter. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience during the 3rd quarter valued at about $43,992,000. Wellington Management Group LLP lifted its holdings in shares of Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares during the last quarter. Finally, Fred Alger Management LLC grew its position in Twist Bioscience by 17.1% in the third quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after acquiring an additional 112,272 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.